The research paper I am presenting focuses on the BRCA2 Gene—a tumor suppressor gene that affects the risk of breast and ovarian cancer—and the impacts of its variants. The paper's main goal is to classify the function of the R3052Q variant—which impacts DNA repair efficiency—as a low risk variant.
Breast cancer is a disease where cells in the breast tissue grow uncontrollably and form malignant tumors that can spread throughout the body. Because of the rapid growth of these tumors, many of them have double-strand DNA strand breaks. The DNA-binding domain within the BRCA2 gene recognizes and repairs these breaks with the BRCA2 and RAD51 proteins. The R3052Q variant is located in this DNA-binding domain. The researchers' goal in this paper was to determine if the R3052Q variant inhibits DNA repair efficiency and if it can be classified as a low-risk variant. Researchers were able to determine a cell's DNA repair efficiency with the R3052Q variant by observing the RAD51 protein response after cells went through radiation to create DNA double-strand breaks. They then used immunofluorescence to highlight the RAD51 protein. Under a fluorescence microscope, researchers saw that there was a decrease in the amount of RAD51 protein in the cells with the R3052Q variant. The images showed a decreased amount of RAD51. This implies that the R3052Q variant has an impact on the DNA repair protein response. It also shows that the variant did not eliminate the DNA repair protein response and only inhibited it. The researchers used these results to determine that the R3052Q variant was a hypomorphic variant, which means there is a partial loss in gene function.
Press the pop-out button to view:
ISR 10th grade Elevator speech - Maddie Giarratano-5/17/2026, 4:08 PM.mp4